Dr. Dang Long

Dr. Dang Long

Associate Professor

University of Florida
PO Box 100278, Gainesville, United States of America, 32608

plus Speciality

CANCER

Biography:

Education and Training
1987: AB Biochemistry, Magna Cum Laude, Harvard University, Cambridge, MA.
1994: MD, PhD Immunology, Harvard Medical School, Boston, MA.
Training:
1996: Neurosurgery Resident, University of Minnesota
1998: Internal Medicine Resident, Hospital of the University of Pennsylvania
2003: Oncology Fellowship, Johns Hopkins University School of Medicine

Honors
* 1983- Highland Park High School Salutatorian, Dallas, Texas.
* 1983- National Merit Scholarship.
* 1983-87- Harvard College Scholarship, John Harvard Scholarship, Harvard University.
* 1987- BA Biochemistry, Magna Cum Laude, Harvard University.
* 1987- Elected into Phi Beta Kappa, Harvard University.
* 2003- Young Investigator Award, Johns Hopkins Hospital.

Professional Societies and Memberships
* 2003- American Association for Cancer Research
* 2003- American Society of Clinical Oncology
* 2003-09- Member, University of Michigan Comprehensive Cancer Center
* 2009- Member of NSABP
* 2009- Member, University of Florida Shands Cancer Center
* 2010- Member of SWOG

Academic positions:

Professional Experience
* 7/89-7/92: Harvard Medical School, Graduate Program in Arts and Sciences, Department of Immunology.
Thesis: An analysis of cell-cell interaction and antigen presentation by B lymphocytes. Mentor: Dr. Kenneth L. Rock.
* 7/94-6/96: The University of Minnesota Hospitals & Clinics. Full-time neurosurgery resident. Chairman: Dr. Robert Maxwell.
* 7/96-6/98: Hospital of the University of Pennsylvania. Full-time internal medicine resident.
Chairman: Dr. Edward Holmes.
* 7/98-7/03: The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center. Full-time medical oncology fellow.
Chairman: Dr. Marty Abeloff.
* 7/00-7/03: The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center. Full-time postdoctoral fellow.
Project: Combination bacteriolytic therapy for the treatment of experimental tumors.
Mentor: Dr. Bert Vogelstein.
* 8/03-6/09: The University of Michigan Medical Center, Department of Internal Medicine, Division of Hematology and Oncology. Full-time, tenure track Assistant Professor. Chairman: Dr. Marc Lippman.
* 7/09- The University of Florida College of Medicine, Department of Internal Medicine, Division of Hematology and Oncology. Full-time, tenure track Associate Professor. Co-Director of Oncology Phase I Program.
Chief: Dr. Carmen Allegra.
* 4/11- The University of Florida Shands Cancer Center, Chair of Data Safety Monitoring Board (DSMB).

Research interests:

Cancer, Hematology and Oncology

Any other information:

Bibliography
Peer-reviewed publications:
1. Benacerraf, B, Michalek MT, Dang LH and Rock KL (1989) The importance of antigen processing in determinant selection and of the cell membrane as a reservoir of processed antigen. Cold Spring Harbor Symposia on Quantitative Biology 54: 293.
2. Dang LH, Michalek MT, Take F, Benacerraf B and Rock KL (1990) Role of ICAM-1 in antigen presentation demonstrated by ICAM-1 defective mutants Journal of Immunology 144: 4082-4091, 1990.
3. Dang DH and Rock KL (1991) Stimulation of B lymphocytes through surface Ig receptors induces LFA-1 and ICAM-1 dependent adhesions. Journal of Immunology 146: 3273-3279.
4. Dang LH, Lien LL, Benacerraf B and Rock KL (1993) A mutant APC defective in antigen presentation expresses class II MHC molecules with an altered conformation. Journal of Immunology 150: 4206-4217.
5. Dang DT, Bachman KE, Mahatan CS, Dang LH, Giardiello FM, and Yang VW (2000) Decreased expression of the gut-enriched Krüppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Letters 476: 203-207.
6. Dang DT, Mahatan CS, Dang LH, Agboola IA and Yang VW (2001) Expression of the gut-enriched Krüppel- like factor (Krüppel- like factor 4) gene in the human colon cancer cell line RKO is dependent on CDX2. Oncogene 20(35): 4884-4890.
7. Dang LH, Bettegowda C, Huso DL, Kinzler KW and Vogelstein B (2001) Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 98(26): 15155-60.
8. Chan TA, Wang Z, Dang LH, Vogelstein B, Kinzler KW (2002) Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation. Proc Natl Acad Sci USA 99(12):8265-8270.
9. Dang DT, Chen XM, Feng J, Torbenson M, Dang LH, Yang VW (2003) Over-expression of gut-enriched kruppel-like factor (GKLF or KLF4) in the human colon cancer cell line RKO leads to reduced tumorigenicity. Oncogene, 22:3424-3430.
10. Bettegowda C *, Dang LH *, Abrams R, Huso DL, Dillehay L, Cheong I, Agrawal N, Borzillary S, McCaffery JM, Watson EL, Lin KS, Bunz F, Baidoo K, Pomper M, Kinzler KW, Vogelstein B and Zhou S (2003) Overcoming the Hypoxic Barrier to Radiation Therapy with Anaerobic Bacteria. Proc Natl Acad Sci USA, 100(25): 15083-15088. *these authors contributed equally to this work
11. Dang LH *, Bettegowda C *, Agrawal N, Cheong I, Huso D, Frost P, Loganzo F, Greenberger L, Barkoczy J, Pettit G, Smith A, Gurulingappa H, Khan S, Parmigiani G, Kinzler KW, Zhou S and Vogelstein B (2004) Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-microtubule Agents. Cancer Biology and Therapy, 3(3): 326-337. *these authors contributed equally to this work
12. Agrawal N, Bettegowda C, Cheong I, Geschwind J-F, Drake CG, Hipkiss EL, Tatsumi M, Dang LH, Diaz L, Pomper M, Abusedera M, Wahl RL, Kinzler KW, Zhou S, Huso DL and Vogelstein B (2004) Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci USA, 101(42): 15172-15177.
13. Bettegowda C, Foss CA, Cheong I, Wang Y, Diaz L, Agrawal N, Fox J, Dick J, Dang LH, Zhou S, Kinzler KW, Vogelstein B and Pomper MG (2005) Imaging bacterial infections with radiolabeled 1-(2’-deoxy-2’-fluoro-?-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci USA, 102(4):1145-1150.
14. Dang DT, Chen F, Kohli M, Rago C, Cummins J, and Dang LH (2005) Glutathione S-transferase pi 1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Research, 65(20):9485-9494.
15. Diaz L, Cheong I, Foss C, Zhang X, Peters B, Agrawal N, Bettegowda C, Karim B, Liu G, Khan K, Huang X, Dang LH, Hwang P, Vogelstein A, Kobrin B, Pomper M, Zhou S, Kinzler KW, Vogelstein B, and Huso D (2005) Pharmacologic and Toxicologic Evaluation of C. novyi-NT spores. Toxicol Sci, 88(2):562-575.
16. Dang LH, Chen F, Ying C, Chun SY, Knock SA, Appelman HD, Dang DT (2006) CDX2 has tumorigenic potential in the human colon cancer cell lines LOVO and SW48. Oncogene, 25(15):2264-72.
17. Dang LH, Chen F, Knock SA, Huang EH, Feng J, Appelman HD, Dang DT (2006) CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45. Oncogene 25(14):2048-59.
18. Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV, Dang LH (2006) HIF-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Research, 66(3):1684-96.
19. Chun S, Chen F, Washburn J, MacDonald J, Innes K, Cruz-Correa MR, Dang LH, Dang DT (2007) CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3. Oncogene, [Epub ahead of print].
20. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ (2007) 1α,25-dihydroxyvitamin D3 (Calcitriol) reduces VEGF via the HIF pathway in human cancer cells. Molecular Cancer Therapeutics, 6(4):1433-9.
21. Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Blayney DW, Ensminger WD, St. Croix B, Dang NH, Dang LH (2008) HIF-1 target genes as indicators of tumor vessel response to VEGF inhibition. Cancer Research, 68(6):1872-80.
22. Burkitt K, Chun SY, Dang DT, Dang LH (2009) Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Molecular Cancer Therapeutics, 8(5):1148-56.
23. Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH* (2010). Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1? and HIF-2? target genes. Molecular Cancer, 9:293.
24. Funakoshi S, Kong J, Crissey MA, Dang L, Dang D, Lynch JP (2010). Intestine-specific transcription factor Cdx2 induces E-cadherin function by enhancing the trafficking of E-cadherin to the cell membrane. Am J Physiol Gastrointest Liver Physiol, 299(5):G1054-G1067.
25. Abe M, Havre PA, Urasaki Y, Ohnuma K, Morimoto C, Dang LH, Dang NH (2011). Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines. BMC Cancer, 11:51.
26. Ucar DA, Dang LH, Hochwald SN (2011). Focal adhesion kinase signaling and function in pancreatic cancer. Review. Front Biosci, 3:750-756.
27. Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM (2011). Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene, 30(10):1205-1212.
28. Wenger JB, Chun SY, Dang DT, Luesch H, Dang LH* (2011). Combination therapy targeting cancer metabolism. Review. Medical Hypotheses, 76(2):169-172.
29. Wenger JB, Santos N, Liu Y, Dallas J, Subbiah S, Hochwald S, Huang EH, Dang DT, Allegra CJ, Luesch H*, Dang LH* (2011). Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma? Review. Oncology Reviews, 5:177-184. * co-corresponding authors
30. Santos N, Wenger JB, Havre P, Liu Y, Dagan R, Imanirad I, Ivey AM, Zlotecki RA, Algood CB, Gilbert SM, Allegra CJ, Okunieff P, Vieweg J, Dang NH, Luesch H, Dang LH (2011). Combination therapy for renal cell cancer: what are possible options? Review. Oncology, 81(3-4): 220-229.
31. Dallas J, Imanirad I, Rajani R, Dagan R, Subbiah S, Gaa R, Dwarica WA, Ivey AM, Zlotecki RA, Malyapa R, Indelicato DJ, Scarborough MT, Reith JD, Gibbs CP, Dang LH (2012). Response to sunitinib in combination with proton beam radiation in a patient with chondrosarcoma: a case report. J Med Case Reports, 6(1):41.
32. Michael Vainrib, Maya Golan, Sharon Amir, Duyen T. Dang, Long H. Dang, Anat Bar-Shira, Avi Orr-Urtreger, Haim Matzkin, Nicola J. Mabjeesh (2011). HIF1A C1772T polymorphism leads to HIF-1a mRNA overexpression in prostate cancer patients: a novel HIF-1 gain-of-function mechanism. Manuscript submitted.

Book chapters:
1. Havre PA, Dang LH, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH* (2010). The role of CD26 in T-cell biology and T-cell malignancies. Book Chapter. T-Cell Malignancies: Recent Developments and Novel Therapeutic Approaches.
2. Santos N, Wenger JB, Gupta E, Chan E, Peicher K, Jiang M, Liu Y, Havre P, Dahm P, Su LM, Dang NH, Luesch H, Dang LH (2011). Book Chapter. Can We Develop More Effective Combination Antiangiogenic Therapy for Patients with Cancer?

What I think of the idea behind WebmedCentral and WebmedCentral plus:

I think WebmedCentral is a great idea that will expedite publications.